Loading...
XSTOIBTb
Market cap65mUSD
Dec 23, Last price  
56.00SEK
1D
-5.08%
1Q
71.25%
Jan 2017
42.20%
IPO
1.50%
Name

Infant Bacterial Therapeutics AB

Chart & Performance

D1W1MN
XSTO:IBTb chart
P/E
—
P/S
9,467.71
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.76%
Rev. gr., 5y
22.47%
Revenues
77k
+541.67%
0000162,000238,000000012,00077,000
Net income
-123m
L+89.06%
-1,7050-6,747,000-20,624,000-38,106,000-36,156,000-40,607,000-47,045,000-72,310,000-45,404,000-65,094,000-123,068,000
CFO
-101m
L+17.98%
0-3,772,000-17,024,000-39,748,000-34,763,000-47,409,000-51,301,000-58,389,000-55,623,000-85,795,000-101,219,000
Earnings
Feb 06, 2025

Profile

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
URL
https://ibtherapeutics.com/
IPO date
Mar 29, 2016
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
77
541.67%
12
 
Cost of revenue
135,762
65,820
44,672
Unusual Expense (Income)
NOPBT
(135,685)
(65,808)
(44,672)
NOPBT Margin
Operating Taxes
(357)
413
Tax Rate
NOPAT
(135,685)
(65,451)
(45,085)
Net income
(123,068)
89.06%
(65,094)
43.37%
(45,404)
-37.21%
Dividends
Dividend yield
Proceeds from repurchase of equity
101,545
1,884
91
BB yield
-9.13%
-0.34%
-0.01%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
8,746
Net debt
(329,134)
(335,910)
(386,802)
Cash flow
Cash from operating activities
(101,219)
(85,795)
(55,623)
CAPEX
Cash from investing activities
(4,146)
(1,000)
Cash from financing activities
96,515
1,884
91
FCF
(135,685)
(65,451)
(40,569)
Balance
Cash
329,064
335,840
386,752
Long term investments
70
70
50
Excess cash
329,130
335,909
386,802
Stockholders' equity
(461,676)
(339,220)
(273,768)
Invested Capital
766,830
670,926
669,022
ROIC
ROCE
EV
Common stock shares outstanding
12,365
11,226
11,226
Price
90.00
80.00%
50.00
-25.15%
66.80
-40.36%
Market cap
1,112,815
98.25%
561,309
-25.15%
749,909
-40.36%
EV
783,681
225,399
363,107
EBITDA
(134,869)
(64,992)
(43,856)
EV/EBITDA
Interest
293
413
Interest/NOPBT